Patient-drug precision matching
STALICLA's DEPI technology uses advanced AI analysis to identify patient subgroups with similar disease signatures. It integrates and analyzes large omics data sets, including genomics, transcriptomics, proteomics, pharmacogenomics, and clinical data. DEPI then matches these subgroups with a tailored NDD-targeted drug or drug combination, validated using patient cells, to provide a precision medicine solution.
DEPI's unique drug-patient matching module is accelerating our drug development pipeline. It has achieved clinical proof of concept with the validation of Phenotype 1, supported by studies at Greenwood Genetic Center and Cincinnati Children's Hospital. We have also validated a second ASD subgroup, Phenotype 2 with matching drug candidate STP2. STP1 will advance to phase 2 trials in 2025.